NEUROSCIENCE Correction for “Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers,” by Fernanda G. De Felice, Marcelo N. N. Vieira, Theresa R. Bomfim, Helena Decker, Pauline T. Velasco, Mary P. Lambert, Kirsten L. Viola, Wei-Qin Zhao, Sergio T. Ferreira, and William L. Klein, which appeared in issue 6, February 10, 2009, of Proc Natl Acad Sci USA (106:1971–1976; first published February 2, 2009; 10.1073/pnas.0809158106).
The authors would like to declare the following conflict of interest. “W.L.K. is cofounder of Acumen Pharmaceuticals, which has been licensed by Northwestern University to develop ADDL technology for Alzheimer's therapeutics and diagnostics.”